Treatment of motor fluctuations in Parkinson's disease: Recent developments and future directions

Expert Review of Neurotherapeutics

Volumn 14, Issue 1, 2014, Pages 93-103

  Ramirez Zamora, Adolfo ^a   Molho, Eric ^a  

^a ALBANY MEDICAL CENTER   (United States)

Author keywords

Deep brain stimulation; Dopaminergic treatment; Dyskinesias; Parkinson's disease; Wearing off

Indexed keywords

ADENOSINE A2A RECEPTOR ANTAGONIST; ADRENERGIC RECEPTOR BLOCKING AGENT; AMANTADINE; APOMORPHINE; CARBIDOPA; CARBIDOPA PLUS LEVODOPA; FIPAMEZOLE; GLUTAMATE RECEPTOR ANTAGONIST; IDAZOXAN; ISTRADEFYLLINE; LEVODOPA; MAVOGLURANT; MONOAMINE OXIDASE INHIBITOR; PARDOPRUNOX; PERAMPANEL; PICLOZOTAN; PRAMIPEXOLE; PRELADENANT; REMACEMIDE; ROPINIROLE; ROTIGOTINE; SAFINAMIDE; SARIZOTAN; SEROTONIN AGONIST; UNCLASSIFIED DRUG; XP 21279; ZONISAMIDE;

ADD ON THERAPY; BEHAVIOR CHANGE; BRADYKINESIA; DIZZINESS; DOPAMINERGIC NERVE CELL; DRUG DELIVERY SYSTEM; DRUG DOSE ESCALATION; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSKINESIA; FATIGUE; HALLUCINATION; HUMAN; IMPULSE CONTROL DISORDER; LOCAL SKIN REACTION; MOTOR DYSFUNCTION; MUSCLE RIGIDITY; NAUSEA; NERVE DEGENERATION; NEUROMODULATION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SOMNOLENCE; SUBCUTANEOUS NODULE; TREATMENT OUTCOME; TREMOR; VOMITING;

ANTIPARKINSON AGENTS; DEEP BRAIN STIMULATION; HUMANS; PARKINSON DISEASE;

EID: 84893152168     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.2014.868306     Document Type: Review

References (84)

1. Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov. Disord. 16(3), 448-458 (2001
2. Chapuis S, Ouchchane L, Metz O, Gerbaud L, Durif F. Impact of the motor complications of Parkinson's disease on the quality of life. Mov. Disord. 20(2), 224-230 (2005
3. Hauser RA, Deckers F, Lehert P. Parkinson's disease home diary: Faurther validation and implications for clinical trials. Mov. Disord. 19(12), 1409-1413 (2004
4. Kalia LV, Brotchie JM, Fox SH. Novel nondopaminergic targets for motor features of Parkinson's disease: Review of recent trials. Mov. Disord. 28(2), 131-144 (2013
5. Schwarzschild MA, Agnati L, Fuxe K, Chen JF, Morelli M. Targeting adenosine A2A receptors in Parkinson's disease. Trends Neurosci. 29(11), 647-654 (2006
6. Shiozaki S, Ichikawa S, Nakamura J, Kitamura S, Yamada K, Kuwana Y. Actions of adenosine A2A receptor antagonist KW-6002 on drug-induced catalepsy and hypokinesia caused by reserpine or MPTP. Psychopharmacology 147(1), 90-95 (1999
7. Kanda T, Jackson MJ, Smith LA et al. Adenosine A2A antagonist: A novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys. Ann. Neurol. 43(4), 507-513 (1998
8. Abstracts of the 8th International Congress of Parkinson's Disease and Movement Disorders. June 14-17, 2004. Rome, Italy. Mov. Disord. 19(Suppl. 9), S1-S491 (2004
9. LeWitt PA, Guttman M, Tetrud JW et al. Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces "off" time in Parkinson's disease: A double-blind, randomized, multicenter clinical trial (6002- US-005). Ann. Neurol. 63(3), 295-302 (2008
10. Hauser RA, Shulman LM, Trugman JM et al. Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations. Mov. Disord. 23(15), 2177-2185 (2008
11. Mizuno Y, Hasegawa K, Kondo T, Kuno S, Yamamoto M; Japanese Istradefylline Study Group. Clinical efficacy of istradefylline (KW-6002) in Parkinson's disease: A randomized, controlled study. Mov. Disord. 25(10), 1437-1443 (2010
12. Mizuno Y, Kondo T; Japanese Istradefylline Study Group. Adenosine A2A receptor antagonist istradefylline reduces daily OFF time in Parkinson's disease. Mov. Disord. 28(8), 1138-1141 (2013
13. Pourcher E, Fernandez HH, Stacy M, Mori A, Ballerini R, Chaikin P. Istradefylline for Parkinson's disease patients experiencing motor fluctuations: Results of the KW-6002-US-018 study. Parkinsonism Relat. Disord. 18(2), 178-184 (2012
14. Factor S, Mark MH, Watts R et al. A long-term study of istradefylline in subjects with fluctuating Parkinson's disease. Parkinsonism Relat. Disord. 16(6), 423-426 (2010
15. Hauser RA, Cantillon M, Pourcher E et al. Preladenant in patients with Parkinson's disease and motor fluctuations: A phase 2, double-blind, randomised trial. Lancet Neurol. 10(3), 221-229 (2011
16. Factor SA, Wolski K, Togasaki DM et al. Long-term safety and efficacy of preladenant in subjects with fluctuating Parkinson's disease. Mov. Disord. 28(6), 817-820 (2013
17. Stocchi F, Borgohain R, Onofrj M et al. A randomized, double-blind, placebo-controlled trial of safinamide as add-on therapy in early Parkinson's disease patients. Mov. Disord. 27(1), 106-112 (2012
18. Barone P, Fernandez H, Ferreira J et al. Safinamide as an add-on therapy to a stable dose of a single dopamine agonist: Results from a randomized, placebo-controlled, 24-week multicenter trial in early idiopathic Parkinson disease (PD) patients (MOTION Study). Neurology 80(Meeting Abstracts 1), P01.061 (2013
19. Schapira AH, Fox S, Hauser R et al. Safinamide add on to L-dopa: A randomized, placebo-controlled, 24-week global trial in patients with Parkin- son's disease (PD) and motor fluctuations (SETTLE). Neurology 80(Meeting Abstracts 1), P01.062 (2013
20. Gregoire L, Jourdain VA, Townsend M, Roach A, Di Paolo T. Safinamide reduces dyskinesias and prolongs l-DOPA antiparkinsonian effect in parkinsonian monkeys. Parkinsonism Relat. Disord. 19(5), 508-514 (2013
21. Murata M, Hasegawa K, Kanazawa I; Japan Zonisamide on PDSG. Zonisamide improves motor function in Parkinson disease: A randomized, double-blind study. Neurology 68(1), 45-50 (2007
22. Mochio S, Sengoku R, Kono Y et al. Actigraphic study of tremor before and after treatment with zonisamide in patients with Parkinson's disease. Parkinsonism Relat. Disord. 18(7), 906-908 (2012
23. Jenner P. Molecular mechanisms of L-DOPA-induced dyskinesia. Nat. Rev. Neurosci. 9(9), 665-677 (2008
24. Snow BJ, Macdonald L, McAuley D, Wallis W. The effect of amantadine on levodopa-induced dyskinesias in Parkinson's disease: A double-blind, placebo-controlled study. Clin. Neuropharmacol. 23(2), 82-85 (2000
25. Thomas A, Iacono D, Luciano AL, Armellino K, Di Iorio A, Onofrj M. Duration of amantadine benefit on dyskinesia of severe Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 75(1), 141-143 (2004
26. Wolf E, Seppi K, Katzenschlager R et al. Long-term antidyskinetic efficacy of amantadine in Parkinson's disease. Mov. Disord. 25(10), 1357-1363 (2010
27. Gasparini F, Di Paolo T, Gomez-Mancilla B. Metabotropic glutamate receptors for Parkinson's disease therapy. Parkinsons Dis. 2013, 196028 (2013
28. Lees A, Fahn S, Eggert KM et al. Perampanel, an AMPA antagonist, found to have no benefit in reducing "off" time in Parkinson's disease. Mov. Disord. 27(2), 284-288 (2012
29. Rascol O, Barone P, Behari M et al. Perampanel in Parkinson disease fluctuations: A double-blind randomized trial with placebo and entacapone. Clin. Neuropharmacol. 35(1), 15-20 (2012
30. Clarke CE, Cooper JA, Holdich TA, Group TS. A randomized, double-blind, placebo-controlled, ascending-dose tolerability and safety study of remacemide as adjuvant therapy in Parkinson's disease with response fluctuations. Clin. Neuropharmacol. 24(3), 133-138 (2001
31. Shoulson I, Penney J, McDermott M et al. A randomized, controlled trial of remacemide for motor fluctuations in Parkinson's disease. Neurology 56(4), 455-462 (2001
32. Mela F, Marti M, Dekundy A, Danysz W, Morari M, Cenci MA. Antagonism of metabotropic glutamate receptor type 5 attenuates l-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease. J. Neurochem. 101(2), 483-497 (2007
33. Johnston TH, Fox SH, McIldowie MJ, Piggott MJ, Brotchie JM. Reduction of L-DOPA-induced dyskinesia by the selective metabotropic glutamate receptor 5 antagonist 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl]pyridine in the 1-methyl-4-phenyl- 1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease. J. Pharmacol. Exp. Ther. 333(3), 865-873 (2010
34. Berg D, Godau J, Trenkwalder C et al. AFQ056 treatment of levodopa-induced dyskinesias: Results of 2 randomized controlled trials. Mov. Disord. 26(7), 1243-1250 (2011
35. Stocchi F, Rascol O, Destee A et al. AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study. Mov. Disord. (2013
36. Barnum CJ, Bhide N, Lindenbach D et al. Effects of noradrenergic denervation on L-DOPA-induced dyskinesia and its treatment by alpha- and beta-adrenergic receptor antagonists in hemiparkinsonian rats. Pharmacol. Biochem. Behav. 100(3), 607-615 (2012
37. Brotchie JM. Nondopaminergic mechanisms in levodopa-induced dyskinesia. Mov. Disord. 20(8), 919-931 (2005
38. Halliday GM, Blumbergs PC, Cotton RG, Blessing WW, Geffen LB. Loss of brainstem serotonin- and substance P-containing neurons in Parkinson's disease. Brain Res. 510(1), 104-107 (1990
39. Hill MP, Brotchie JM. The adrenergic receptor agonist, clonidine, potentiates the anti-parkinsonian action of the selective kappa-opioid receptor agonist, enadoline, in the monoamine-depleted rat. Br. J. Pharmacol. 128(7), 1577-1585 (1999
40. Srinivasan J, Schmidt WJ. The effect of the alpha2-adrenoreceptor antagonist idazoxan against 6-hydroxydopamine-induced Parkinsonism in rats: Multiple facets of action? Naunyn Schmiedebergs Arch. Pharmacol. 369(6), 629-638 (2004
41. Henry B, Fox SH, Peggs D, Crossman AR, Brotchie JM. The alpha2-adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances anti-parkinsonian actions of L-dopa in the MPTP-lesioned primate model of Parkinson's disease. Mov. Disord. 14(5), 744-753 (1999
42. Savola JM, Hill M, Engstrom M et al. Fipamezole (JP-1730) is a potent alpha2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease. Mov. Disord. 18(8), 872-883 (2003
43. Lewitt PA, Hauser RA, Lu M et al. Randomized clinical trial of fipamezole for dyskinesia in Parkinson disease (FJORD study). Neurology 79(2), 163-169 (2012
44. Olanow CW, Damier P, Goetz CG et al. Multicenter, open-label, trial of sarizotan in Parkinson disease patients with levodopa-induced dyskinesias (the SPLENDID Study). Clin. Neuropharmacol. 27(2), 58-62 (2004
45. Goetz CG, Damier P, Hicking C et al. Sarizotan as a treatment for dyskinesias in Parkinson's disease: A double-blind placebocontrolled trial. Mov. Disord. 22(2), 179-186 (2007
46. Pahwa R, Factor SA, Lyons KE et al. Practice parameter: Treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): Report of the quality standards subcommittee of the American Academy of Neurology. Neurology 66(7), 983-995 (2006
47. Calandrella D, Antonini A. Pulsatile or continuous dopaminomimetic strategies in Parkinson's disease. Parkinsonism Relat. Disord. 18(Suppl. 1), S120-S122 (2012
48. Katzenschlager R, Hughes A, Evans A et al. Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: A prospective study using single-dose challenges. Mov. Disord. 20(2), 151-157 (2005
49. Cereceda-Balic F, Kleist E, Prast H, Schlimper H, Engel H, Gunther K. Description and evaluation of a sampling system for long-time monitoring of PAHs wet deposition. Chemosphere 49(3), 331-340 (2002
50. van Laar T, van der Geest R, Danhof M, Bodde HE, Goossens PH, Roos RA. Stepwise intravenous infusion of apomorphine to determine the therapeutic window in patients with Parkinson's disease. Clin. Neuropharmacol. 21(3), 152-158 (1998
51. Pfeiffer RF, Gutmann L, Hull KL, Jr., Bottini PB, Sherry JH, Investigators APOS. Continued efficacy and safety of subcutaneous apomorphine in patients with advanced Parkinson's disease. Parkinsonism Relat. Disord. 13(2), 93-100 (2007
52. De Gaspari D, Siri C, Landi A et al. Clinical and neuropsychological follow up at 12 months in patients with complicated Parkinson's disease treated with subcutaneous apomorphine infusion or deep brain stimulation of the subthalamic nucleus. J. Neurol. Neurosurg. Psychiatry 77(4), 450-453 (2006
53. Tyne HL, Parsons J, Sinnott A, Fox SH, Fletcher NA, Steiger MJ. A 10 year retrospective audit of long-term apomorphine use in Parkinson's disease. J. Neurol. 251(11), 1370-1374 (2004
54. Antonini A, Odin P. Pros and cons of apomorphine and L-dopa continuous infusion in advanced Parkinson's disease. Parkinsonism Relat. Disord. 15(Suppl. 4), S97-S100 (2009
55. Pahwa R, Stacy MA, Factor SA et al. Ropinirole 24-hour prolonged release: Randomized, controlled study in advanced Parkinson disease. Neurology 68(14), 1108-1115 (2007
56. Zhang Z, Wang J, Zhang X et al. The efficacy and safety of ropinirole prolonged release tablets as adjunctive therapy in Chinese subjects with advanced Parkinson's disease: A multicenter, double-blind, randomized, placebo-controlled study. Parkinsonism Relat. Disord. 19(11), 1022-1026 (2013
57. Watts RL, Jankovic J, Waters C, Rajput A, Boroojerdi B, Rao J. Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease. Neurology 68(4), 272-276 (2007
58. LeWitt PA, Lyons KE, Pahwa R, Group SPS. Advanced Parkinson disease treated with rotigotine transdermal system: PREFER Study. Neurology 68(16), 1262-1267 (2007
59. Schapira AH, Barone P, Hauser RA et al. Extended-release pramipexole in advanced Parkinson disease: A randomized controlled trial. Neurology 77(8), 767-774 (2011
60. Samanta J, Hauser RA. Duodenal levodopa infusion for the treatment of Parkinson's disease. Expert Opin. Pharmacother. 8(5), 657-664 (2007
61. Nyholm D, Nilsson Remahl AI, Dizdar N et al. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease. Neurology 64(2), 216-223 (2005
62. Nyholm D. Enteral levodopa/carbidopa gel infusion for the treatment of motor fluctuations and dyskinesias in advanced Parkinson's disease. Expert Rev. Neurother. 6(10), 1403-1411 (2006
63. Fernandez HH, Odin P. Levodopa-carbidopa intestinal gel for treatment of advanced Parkinson's disease. Curr. Med. Res. Opin. 27(5), 907-919 (2011
64. Fernandez HH, Vanagunas A, Odin P et al. Levodopa-carbidopa intestinal gel in advanced Parkinson's disease open-label study: Interim results. Parkinsonism Relat. Disord. 19(3), 339-345 (2013
65. Djaldetti R, Giladi N, Hassin-Baer S, Shabtai H, Melamed E. Pharmacokinetics of etilevodopa compared to levodopa in patients with Parkinson's disease: An open-label, randomized, crossover study. Clin. Neuropharmacol. 26(6), 322-326 (2003
66. Juncos JL, Mouradian MM, Fabbrini G, Serrati C, Chase TN. Levodopa methyl ester treatment of Parkinson's disease. Neurology 37(7), 1242-1245 (1987
67. Lewitt PA, Ellenbogen A, Chen D et al. Actively transported levodopa prodrug XP21279: A study in patients with Parkinson disease who experience motor fluctuations. Clin. Neuropharmacol. 35(3), 103-110 (2012
68. Hauser RA, Ellenbogen AL, Metman LV et al. Crossover comparison of IPX066 and a standard levodopa formulation in advanced Parkinson's disease. Mov. Disord. 26(12), 2246-2252 (2011
69. Hauser RA, Hsu A, Kell S et al. Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson's disease and motor fluctuations: A phase 3 randomised, double-blind trial. Lancet Neurol. 12(4), 346-356 (2013
70. Weaver FM, Follett K, Stern M et al. Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: A randomized controlled trial. JAMA 301(1), 63-73 (2009
71. Williams A, Gill S, Varma T et al. Deep brain stimulation plus best medical therapy versus best medical therapy alone for advanced Parkinson's disease (PD SURG trial): A randomised, open-label trial. Lancet Neurol. 9(6), 581-591 (2010
72. Deuschl G, Schade-Brittinger C, Krack P et al. A randomized trial of deep-brain stimulation for Parkinson's disease. N. Engl. J. Med. 355(9), 896-908 (2006
73. Moro E, Lozano AM, Pollak P et al. Long-term results of a multicenter study on subthalamic and pallidal stimulation in Parkinson's disease. Mov. Disord. 25(5), 578-586 (2010
74. Follett KA, Weaver FM, Stern M et al. Pallidal versus subthalamic deep-brain stimulation for Parkinson's disease. N. Engl. J. Med. 362(22), 2077-2091 (2010
75. Duker AP, Espay AJ. Surgical treatment of Parkinson disease: Past, present, and future. Neurol. Clin. 31(3), 799-808 (2013
76. Rosin B, Slovik M, Mitelman R et al. Closed-loop deep brain stimulation is superior in ameliorating parkinsonism. Neuron 72(2), 370-384 (2011
77. Gross RE, McDougal ME. Technological advances in the surgical treatment of movement disorders. Curr. Neurol. Neurosci. Rep. 13(8), 371 (2013
78. Schuepbach WM, Rau J, Knudsen K et al. Neurostimulation for Parkinson's disease with early motor complications. N. Engl. J. Med. 368(7), 610-622 (2013
79. Santos-Garcia D, de la Fuente-Fernandez R. Impact of non-motor symptoms on the quality of life of patients with Parkinson's disease: Some questions beyond research findings. J. Neurol. Sci. doi:10.1016/j. jns.2013.09.012 (2013) (Epub ahead of print
80. Chaudhuri KR, Martinez-Martin P, Schapira AH et al. International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson's disease: The NMSQuest study. Mov. Disord. 21(7), 916-923 (2006
81. Chaudhuri KR, Martinez-Martin P, Brown RG et al. The metric properties of a novel non-motor symptoms scale for Parkinson's disease: Results from an international pilot study. Mov. Disord. 22(13), 1901-1911 (2007
82. Honig H, Antonini A, Martinez-Martin P et al. Intrajejunal levodopa infusion in Parkinson's disease: A pilot multicenter study of effects on nonmotor symptoms and quality of life. Mov. Disord. 24(10), 1468-1474 (2009
83. Pursiainen V, Lyytinen J, Pekkonen E. Effect of duodenal levodopa infusion on blood pressure and sweating. Acta Neurol. Scand. 126(4), e20-e24 (2012
84. Ray Chaudhuri K, Martinez-Martin P, Antonini A et al. Rotigotine and specific non-motor symptoms of Parkinson's disease: Post hoc analysis of RECOVER. Parkinsonism Relat. Disord. 19(7), 660-665 (2013